


# Appendix F

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

Date	Activity	IND 45,457	Comments
3-Jun-94	Submission to FDA	0	IND submission
13-Jun-94	Letter from the FDA	X	Confirmation of IND number
29-Jun-94	Fax from FDA	X	Clinical comments on protocol 137-101
1-Jul-94	Submission to FDA	1	CMC update
5-Jul-94	FDA log	X	Request for information on blinding. Comments on 137-101
6-Jul-94	Submission to FDA	2	137-101 protocol amendment
11-Jul-94	Submission to FDA	3	137-101 protocol amendment
4-Aug-94	Submission to FDA	4	CMC update, Sample of patient record sheet
27-Oct-94	Submission to FDA	5	Transfer of IND to NY group
22-Nov-94	Submission to FDA	6	CMC update
13-Jan-95	Letter from the FDA	X	CMC comments
28-Feb-95	Submission to FDA	8	IND safety report
5-Apr-95	Submission to FDA	9	Response to CMC questions (January 13, 1995)
14-Apr-95	Submission to FDA	10	94CE38-0670 new protocol, CMC update, 137-212 report
5-May-95	Submission to FDA	10	94CE38-0670 new investigator
22-May-95	Letter from the FDA	X	CMC comments
8-Aug-95	Submission to FDA	11	94CE38-0670 protocol amendment
11-Aug-95	Submission to FDA	12	94CE38-0670 new investigator
15-Aug-95	Submission to FDA	13	137-101 protocol amendment
22-Sep-95	Submission to FDA	14	137-101 protocol amendment
22-Sep-95	Submission to FDA	15	Response to CMC questions (May 22, 1995)
25-Sep-95	Submission to FDA	16	95-CE38-0666 new protocol, new investigator, CMC update
29-Sep-95	Letter from the FDA	X	94CE38-0670 comments
19-Oct-95	Submission to FDA	17	95-CE38-0666 new investigator
29-Dec-95	Submission to FDA	18	Annual report
13-Feb-96	Submission to FDA	19	Update to PK&ME and Tox (reports)
8-Mar-96	Submission to FDA	20	Response to comment on 94CE38-0670
7-Aug-96	Submission to FDA	21	Annual report
4-Oct-96	Submission to FDA	22	Toxicology report 94-751-08
10-Feb-97	Submission to FDA	23	Updated IB
29-Jul-97	Submission to FDA	24	Annual report
15-May-98	Submission to FDA	25	137-103 new protocol
29-Jun-98	Submission to FDA	26	IND safety report
15-Jul-98	Submission to FDA	27	Annual report
26-Aug-98	Submission to FDA	28	New IB (July 1998)
11-Sep-98	Submission to FDA	29	CMC amendment



**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
23-Sep-98	Submission to FDA	30	CMC amendment
14-Oct-98	Submission to FDA	31	Follow up IND safety report
30-Oct-98	Submission to FDA	32	137-103 protocol amendment
8-Mar-99	FDA Log	X	EOP 2 meeting discussion
15-Mar-99	Submission to FDA	33	EOP 2 meeting request
16-Apr-99	FDA Log	X	Phone conversation: EOP 2 meeting attendees (pharm/tox)
4-May-99	Submission to FDA	34	Briefing package for EOP 2 meeting
19-May-99	FDA Log	X	Phone conversation: Date, time and attendees for EOP 2 meeting
27-May-99	Submission to FDA	35	Overheads for EOP 2 meeting
4-Jun-99	FDA Log	X	Pfizer executive summary from EOP 2 meeting, June 1, 1999
14-Jun-99	FDA Log	X	Pfizer meeting minutes from EOP 2 meeting, June 1, 1999
17-Jun-99	Fax from FDA	X	Requesting clarification of pre-clinical studies
24-Jun-99	FDA Log	X	Fax: Request for EKG data
1-Jul-99	Fax from FDA	X	FDA EOP 2 meeting minutes
1-Jul-99	FDA log	X	Phone conversation: Updated list of submitted tox reports
13-Jul-99	Submission to FDA	36	Annual report
29-Jul-99	FDA log	X	Phone conversation: Pediatric protocols
2-Aug-99	Submission to FDA	37	Addendum to toxicology report 94-751-08
23-Aug-99	Submission to FDA	38	Outline of proposed pediatric program
24-Aug-99	Submission to FDA	39	New IB (July 1999)
24-Sep-99	Submission to FDA	40	Follow up IND safety report
13-Oct-99	Submission to FDA	41	Revised draft A1371001 for comments
2-Nov-99	FDA log	X	Phone conversation: Scheduling of pediatric meeting
12-Nov-99	FDA log	X	Pfizer meeting minutes from pediatric discussion
17-Nov-99	FDA log	X	Phone conversation: Information request regarding meeting attendees
24-Nov-99	FDA log	X	Fax: Comments on Protocol A1371001
1-Dec-99	Fax from FDA	X	FDA meeting minutes from pediatric discussion
3-Dec-99	Submission to FDA	42	Response to comments on protocol A1371001, request for teleconference
3-Dec-99	FDA log	X	Phone conversation: Scheduling of A1371001 teleconference
10-Dec-99	FDA log	X	Executive summary from teleconference discussing A1371001
14-Dec-99	FDA log	X	Pfizer meeting minutes from teleconference discussing A1371001
13-Jan-00	FDA log	X	FDA meeting minutes from December 9, 1999 teleconference
18-Jan-00	FDA log	X	Phone conversation: Possible teleconference discussion simulation testing
28-Jan-00	Submission to FDA	43	Comments on FDA meeting minutes from December 9, 1999
3-Feb-00	Submission to FDA	44	A1371001 simulation testing
18-Feb-00	FDA log	X	Phone conversation: Confirmation on 1001 teleconference

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
22-Feb-00	Submission to FDA	45	CMC update
3-Mar-00	Submission to FDA	46	A1371001 new protocol
21-Mar-00	Submission to FDA	47	CMC update
23-Mar-00	FDA log	X	FDA meeting minutes from February 23, 2000 teleconference
10-Apr-00	FDA log	X	Comments on protocol A1371001
26-Apr-00	Submission to FDA	48	A1371001 new investigators
1-May-00	Submission to FDA	49	A1371001 protocol amendment
4-May-00	Submission to FDA	50	137-103 protocol amendment
9-May-00	Submission to FDA	51	Response for comments on A1371001 protocol (April 10, 2000)
9-May-00	Submission to FDA	52	CMC update
17-May-00	Submission to FDA	53	A1371001 new investigators
6-Jun-00	Submission to FDA	54	Pharmacology/Toxicology reports 93043 and 93073
6-Jun-00	Submission to FDA	55	A1371001 new investigators
5-Jul-00	FDA log	X	Request for electronic copy of statistics for Carcinogenicity study reports
6-Jul-00	Submission to FDA	56	A1371014 new protocol
6-Jul-00	Submission to FDA	57	CMC update
13-Jul-00	Submission to FDA	58	A1371001 new investigators
17-Jul-00	Submission to FDA	59	137-103 new investigator
24-Jul-00	FDA log	X	Phone conversation: Request for electronic datasets for carcinogenicity studies
8-Aug-00	Submission to FDA	60	A1371001 new investigators, A1371014 new investigators
11-Aug-00	Submission to FDA	61	Annual report
17-Aug-00	Submission to FDA	62	Request for information - global protocol
17-Aug-00	Submission to FDA	63	Electronic datasets for carcinogenicity studies
24-Aug-00	Submission to FDA	64	A1371001 new investigators, A1371014 new investigators
28-Aug-00	FDA log	X	Phone conversation: Global protocol
22-Sep-00	Submission to FDA	65	A1371001 new investigators, A1371014 new investigators
4-Oct-00	Submission to FDA	66	Request for information - patient profiles and safety narratives
16-Oct-00	FDA log	X	Toxicology information request (protein binding)
18-Oct-00	Submission to FDA	67	A1371001 new investigators, A1371014 new investigators
18-Oct-00	Submission to FDA	68	Request for CMC EOP2 meeting
24-Oct-00	FDA Log	X	Phone conversation: Requirement for patient profiles and safety narratives
30-Oct-00	FDA log	X	Phone conversation: Request for tox information
31-Oct-00	FDA log	X	CMC EOP2 meeting scheduling
2-Nov-00	FDA log	X	Fax: Confirmation of CMC EOP2 meeting
3-Nov-00	Submission to FDA	69	A1371014 new investigators
3-Nov-00	Submission to FDA	70	Pharmacology/Toxicology report 94-24-81

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
7-Nov-00	Submission to FDA	71	Response to request: Historical control data for adrenal corticoadenomas
13-Nov-00	Submission to FDA	72	Pre-meeting briefing package - EOP2 CMC meeting
13-Nov-00	FDA log	X	Fax: Confirmation of agreement of patient profiles and safety narratives
22-Nov-00	FDA log	X	Phone conversation: Tox data (carc) request
1-Dec-00	Submission to FDA	73	A1371014 new investigators
5-Dec-00	Submission to FDA	74	Carcinogenicity data
11-Dec-00	Submission to FDA	75	A1371014 new investigators
12-Dec-00	Submission to FDA	76	IB update
13-Dec-00	FDA log	X	Phone conversation: CMC EOP 2 meeting
14-Dec-00	Submission to FDA	77	Change indication from UUI to OAB
15-Dec-00	FDA log	X	Phone conversation: FDA requests carcinogenicity information
2-Jan-01	Submission to FDA	78	Pfizer meeting minutes from EOPII CMC meeting December 14, 2000
12-Jan-01	Submission to FDA	79	A1371014 new investigators
18-Jan-01	Submission to FDA	80	Response to request for information - toxicology data
7-Feb-01	Submission to FDA	81	A1371014 new investigators
20-Mar-01	Submission to FDA	82	A1371018 new protocol, A1371027 new protocol, A1371014 new investigator
9-Apr-01	Submission to FDA	83	CMC update
9-Apr-01	Submission to FDA	84	Meeting request - pediatric meeting
12-Apr-01	FDA log	X	Phone conversation, pediatric meeting
30-Apr-01	Submission to FDA	85	Meeting request for pediatric meeting
10-May-01	Submission to FDA	86	A1381018 new investigators, labeling
15-May-01	Submission to FDA	87	IND safety report
15-May-01	FDA log	X	Phone conversation, pediatric meeting
23-May-01	FDA log	X	Letter from the FDA: Confirmation of pediatric meeting
6-Jun-01	Submission to FDA	88	Pre-meeting briefing package - pediatric meeting
7-Jun-01	Submission to FDA	89	A1371018 protocol amendment
14-Jun-01	Submission to FDA	90	A1371027 new investigators
14-Jun-01	FDA log	X	Phone conversation: Pediatric meeting and CTD discussion
11-Jul-01	FDA log	X	Pfizer minutes of the July 11, 2001 pediatric meeting
18-Jul-01	Submission to FDA	91	A1371027 new investigators
19-Jul-01	Submission to FDA	92	A1371014 amendment
20-Jul-01	Submission to FDA	93	Pfizer minutes of the July 11, 2001 pediatric meeting
25-Jul-01	Submission to FDA	94	Annual report
2-Aug-01	FDA log	X	Phone conversation: Information request on subject 0433-13 in study A1371005
7-Aug-01	Submission to FDA	95	Updated IB
9-Aug-01	FDA log	X	Fax: FDA meeting minutes for pediatric meeting July 11, 2001

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
10-Aug-01	Submission to FDA	96	Clinical safety - follow up information for 0443-13 in study A1371005
20-Aug-01	Letter from the FDA	X	Comments on protocols A1371018 and A1371027
21-Aug-01	Submission to FDA	97	Meeting request for CTD meeting
23-Aug-01	Submission to FDA	98	New investigators
5-Sep-01	FDA log	X	Request for addition information for #0443-13 in study A1371005
5-Sep-01	FDA log	X	Phone conversation and fax: CTD meeting denied
10-Sep-01	Submission to FDA	99	New IB (August 2001)
10-Sep-01	Submission to FDA	100	Tox report 89026
10-Sep-01	FDA log	X	Phone conversation: CTD meeting denied
19-Sep-01	Submission to FDA	101	Clinical safety - follow up information for 0443-13 in study A1371005
24-Sep-01	Submission to FDA	102	New investigators
16-Oct-01	Submission to FDA	103	A1371027 protocol amendment, new investigators
17-Oct-01	Submission to FDA	104	Request for guidance on electronic datasets
23-Oct-01	FDA log	X	CTD Guidance - Randy Levin
24-Oct-01	FDA log	X	CTD Guidance - Randy Levin
5-Nov-01	FDA log	X	CTD Guidance - Randy Levin
7-Nov-01	Submission to FDA	105	Request for trademark review
15-Nov-01	Submission to FDA	106	A1371041 New Protocol, CMC information
28-Nov-01	FDA log	X	Phone conversation: Request for labeling information for trademark review
3-Dec-01	FDA log	X	CTD Guidance - Randy Levin
5-Dec-01	FDA log	X	Letter from FDA: FDA comments on proposed data components for darifenacin electronic submission
20-Dec-01	Submission to FDA	107	Administrative pre-NDA meeting request
21-Dec-01	Submission to FDA	108	Response to request of labeling information - trademark review
3-Jan-02	Submission to FDA	109	A1371041 Labeling, new investigators
3-Jan-02	Submission to FDA	110	New investigators
4-Jan-02	Submission to FDA	111	A1371041 New investigators
21-Jan-02	Submission to FDA	112	A1371042 New Protocol, A1371041 New Investigators
28-Jan-02	FDA log	X	Letter from FDA: Pre-NDA meeting administrative meeting - confirmation
29-Jan-02	Submission to FDA	113	A1371047 New Protocol, A1371041 Country specific protocol amendment and new investigators
30-Jan-02	Submission to FDA	114	Briefing package for administrative pre-NDA meeting
8-Feb-02	FDA log	X	Phone conversation: Pre-NDA administrative meeting discussion, cancellation
12-Feb-02	Submission to FDA	115	A1371042 protocol amendment, A1371031 New Investigators
14-Feb-02	Submission to FDA	116	Postpone administrative pre-NDA meeting
6-Mar-02	Submission to FDA	117	Request for CTD information (administrative)

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
13-Mar-02	Submission to FDA	118	A1371041 country specific amendments, new investigators A1371042 country specific amendment
15-Mar-02	FDA log	X	Phone conversation: CTD question to Division sent out on consult
18-Mar-02	Letter from the FDA	X	Clinical Trials Data Bank
20-Mar-02	Letter from the FDA		Request for information - Clinical Safety (#0443-13 - A1371005)
9-Apr-02	Submission to FDA	119	A1371041 new investigators, Toxicology report 89-751-02
15-Apr-02	Submission to FDA	120	Pre-NDA meeting request
19-Apr-02	Submission to FDA	121	A1371041 New investigators
23-Apr-02	FDA log	X	Phone conversation: CTD discussion with Dr Randy Levin
24-Apr-02	Submission to FDA	122	Follow up Information Amendment - Clinical Safety (#0443-13 - A1371005)
13-May-02	FDA log	X	Letter from FDA: Confirmation of pre-NDA meeting
14-May-02	Submission to FDA	123	Follow up IND safety report
15-May-02	Submission to FDA	124	A1371047 protocol amendments, new investigators, A1371042 new investigators, A1371041 new investigators
15-May-02	Letter from the FDA	X	Clinical Trials Data Bank
17-May-02	Submission to FDA	125	Briefing package for pre-NDA meeting
23-May-02	FDA log	X	Phone conversation: NDA-number, Status of trademark, confirmation of pre-NDA meeting
28-May-02	FDA log	X	Letter from FDA: Comments on protocol 1041
28-May-02	FDA log	X	Letter from FDA: Comments on protocol 1042
31-May-02	FDA log	X	Letter from FDA: Comments on protocol 1047
6-Jun-02	Submission to FDA	126	A1371042 country specific protocol amendments, new investigators, A1371041 new investigators, A1371047 new investigators
11-Jun-02	FDA log	X	E-mail: FDA medical reviewer requested additional information for darifenacin pre-NDA meeting
13-Jun-02	Submission to FDA	127	Response to request from FDA medical reviewer for additional information for darifenacin pre-NDA meeting
17-Jun-02	Submission to FDA	128	Response to comments on A1371041
17-Jun-02	Submission to FDA	129	A1371049 new protocol
18-Jun-02	Submission to FDA	130	Response to comments on A1371042
18-Jun-02	FDA log	X	Pfizer minutes of the June 18, 2002 darifenacin pre-NDA meeting
27-Jun-02	Submission to FDA	131	A1371042 new investigators, A1371047 new investigators
28-Jun-02	Submission to FDA	132	Pfizer meeting minutes from pre-NDA meeting held June 18, 2002
1-Jul-02	Submission to FDA	133	IND safety report
1-Jul-02	Submission to FDA	134	Response to comments on A1371047
3-Jul-02	Submission to FDA	135	A1371042 country specific protocol amendments

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
19-Jul-02	Submission to FDA	136	A1371042 new investigators, A1371047 new investigators
23-Jul-02	FDA log	X	Fax: FDA minutes of the June 18, 2002 darifenacin pre-NDA meeting
1-Aug-02	Submission to FDA	137	A1371042 protocol amendment
7-Aug-02	FDA log	X	Letter from FDA: Comments on Protocol A1371049
12-Aug-02	FDA log	X	Letter from FDA: Comments on Protocol A1371041 (Statistical)
13-Aug-02	Submission to FDA	138	A1371042 new investigators, A1371047 new investigators
21-Aug-02	Submission to FDA	139	Annual report
27-Aug-02	Submission to FDA	140	A1371042 new investigators, A1371047 new investigators
28-Aug-02	Submission to FDA	141	Response to comments on A1371049
30-Aug-02	Submission to FDA	142	Proposed Pediatric Study Request
3-Sep-02	Submission to FDA	143	Response to comments on A1371041 (statistical comments)
4-Sep-02	Submission to FDA	144	Meeting request: Pre-NDA CMC meeting
5-Sep-02	Submission to FDA	145	Pre-meeting questions for teleconference (toxicology)
11-Sep-02	FDA log	X	Fax: CMC pre-NDA meeting confirmation
12-Sep-02	FDA log	X	Fax: CAC meeting minutes and statistical review
17-Sep-02	Submission to FDA	146	A1371042 new investigators, A1371047 new investigators
17-Sep-02	FDA log	X	Teleconference with FDA Toxicology Reviewers - Carcinogenicity
19-Sep-02	Submission to FDA	147	New IB (September 2002)
24-Sep-02	Submission to FDA	148	Pfizer meeting minutes for Sept 17, 2002 with the Pharmacology/Toxicology Reviewer
27-Sep-02	FDA log	X	Letter from FDA: clarification on discrepancy between Pfizer and FDA pre-NDA meeting minutes
27-Sep-02	Submission to FDA	149	Provide an update to the container/closure information
2-Oct-02	Submission to FDA	150	Notify CYP2D6 lab changes for Study 1041
4-Oct-02	Submission to FDA	151	Protocol amendment for 1042
4-Oct-02	FDA log	X	ODS has completed tradename review for darifenacin and concluded that the tradename "ENABLEX" was acceptable
9-Oct-02	Submission to FDA	152	Protocol amendment for 1042 - Canada specific
10-Oct-02	Submission to FDA	153	Notify CYP2D6 lab changes for Study 1047
10-Oct-02	Submission to FDA	154	Briefing information for pre-NDA CMC meeting
10-Oct-02	Letter from the FDA	X	Notify the FADMA requirement for Clinical Trails Data bank
11-Oct-02	Submission to FDA	155	Provide study site information for Studies 1001, 1002, 1011, 1013 and 1041 to assist DSI inspection
16-Oct-02	Submission to FDA	156	Protocol amendment for 1042 - new investigators
18-Oct-02	Submission to FDA	157	Information clarification regarding the Sept 17, 2002 teleconference with the Pharmacology/Toxicology Reviewer

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
7-Nov-02	Submission to FDA	158	Protocol amendment - New Investigators
8-Nov-02	FDA log	X	Pfizer pre-NDA CMC meeting minutes
13-Nov-02	Submission to FDA	159	Follow-up regarding PPSR for darifenacin request for deferral and partial waiver of pediatric studies for darifenacin
14-Nov-02	Submission to FDA	160	Submit the pre-NDA CMC Pfizer meeting minutes
25-Nov-02	Submission to FDA	161	Provide information for Containers and Closures detailing the specifications and suppliers for the packing materials
26-Nov-02	Submission to FDA	162	Protocol amendment for 1042 - New Investigators
27-Nov-02	FDA log	X	FDA meeting minutes for Sept 17, 2002 teleconference with the Toxicology/Pharmacology Reviewer and FDA response regarding the discrepancy with the Pfizer minutes, also provided requested literature reference
27-Nov-02	FDA log	X	FDA response regarding Pfizer's November 8, 2002 letter for management of the Pediatric Rule "requirement" in the NDA submission
27-Nov-02	FDA log	X	Confirmation of paper copies for NDA submission
9-Dec-02	FDA log	X	FDA meeting minutes for November 8, 2002 per-NDA CMC meeting
13-Dec-02	Submission to FDA	163	Protocol amendments for 1042 - New Investigators and revised FDA-1572 forms
30-Dec-02	FDA log	X	Request for additional information for a case of death which causality was attributed to depression resulting in death by suicide, a post-therapy event with regard to darifenacin (not drug related)
30-Dec-02	FDA log	X	FDA comments and recommendations on protocol amendments for Study A1371042 submitted on August 1, October 4, and October 9, 2002
7-Jan-03	Submission to FDA	164	Provide revised 1572 forms
17-Jan-03	FDA log	X	FDA comments and recommendations on protocol A1371047
21-Jan-03	FDA log	X	FDA comments on protocol A1371041
24-Jan-03	Submission to FDA	165	Information amendment - clinical safety
30-Jan-03	FDA log	X	FDA comments regarding darifenacin pediatric plan
21-Feb-03	Submission to FDA	166	Follow-up Safety Letter in response to request for additional information (Dec 19, 2002); regarding safety reference # A201141: copy of death certificate
28-Feb-03	Submission to FDA	167	Submission of revised Investigator 1572 forms
3-Apr-03	Submission to FDA	168	Submission of revised Investigator 1572 forms
23-Apr-03	Submission to FDA	169	Notification of IND Transfer
23-Apr-03	Submission to FDA	170	Change of Ownership from Pfizer to Novartis
07-Jul-03	Submission to FDA	171	Protocol Amendment – New Investigator
28-Jul-03	Submission to FDA	172	Annual Report/Period 4-02 thru 4-03
31-Jul-03	Submission to FDA	173	GenCorr-Transfer of Responsibility (sn logged by va)
31-Jul-03	Submission to FDA	174	GenCorr-Transfer of Responsibility (sn logged by va) Refers to s/n171

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
18-Aug-03	Submission to FDA	175	GenCorr/ New Investigator/chg-complete submission
29-Sep-03	Submission to FDA	176	New Protocol Submission / Study CDAR323A2302
14-Oct-03	FDA log	X	Teleconference with FDA Clinical and Biopharmaceutical discussion of protocol
27-Oct-03	Submission to FDA	177	New Protocol Submission / Study CDAR328A2302
11-Nov-03	Submission to FDA	178	Meeting request – CMC
28-Nov-03	FDA log	X	CMC Meeting confirmation
04-Dec-03	FDA log	X	Protocol comments
04-Dec-03	Submission to FDA	179	Response to information request CMC
05-Dec-03	FDA log	X	Teleconference minutes
10-Dec-03	Submission to FDA	180	Response to /Questions on Draft Prot.
11-Dec-03	Submission to FDA	181	Revised Protocol Submission / Study CDAR328A2302
07-Jan-04	Submission to FDA	182	New Investigator
15-Jan-04	FDA log	X	Teleconference minutes - protocol discussion
19-Jan-04	Submission to FDA	183	New Protocol Submission / Study CDAR328A2302 (response to FDA request for information)
22-Jan-04	FDA log	X	Letter from Division - Agreement with protocol design
23-Jan-04	FDA log	X	Teleconference minutes - protocol discussion
29-Jan-04	Submission to FDA	184	New Protocol Submission / Study CDAR328A2302
12-Feb-04	Submission to FDA	185	GenCorr-Pediatric Deferral & Waiver clarification Request
13-Feb-04	FDA log	X	Teleconference minutes - protocol discussion
27-Feb-04	Submission to FDA	186	New Prot – New Invest
03-Feb-04	Submission to FDA	187	Amend Protocol Submission / Study CDAR328A2302
05-Apr-04	Submission to FDA	188	USED BY OPS//Clinical Inform Amend-Study A1371049
19-Mar-04	Submission to FDA	189	ProtAmend-New Invest
16-Apr-04	Submission to FDA	190	ProtAmend-New Invest Study2401 Center 559
11-May-04	Submission to FDA	191	ProtAmend/Study 2401 New Investigator
07-Jun-04	Submission to FDA	192	ProtAmend – New Invest
08-Jul-04	Submission to FDA	193	ProtAmend – New Invest
09-Jul-04	Submission to FDA	194	ProtAmend – StudyCDAR328A2301
22-Jul-04	Submission to FDA	195	Annual Report 4-4-03 – 3-3-04
02-Aug-04	Submission to FDA	196	ProtAmend – New Investigator
01-Sep-04	Submission to FDA	197	ProtAmend-Studies #CDAR328A2303 & CDAR328A2304
17-Sep-04	Submission to FDA	198	ProtAmend-Studies #CDAR328A2303 & CDAR328A2304

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant during the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>IND 45,457</b>	<b>Comments</b>
10-Jan-04	Submission to FDA	199	Information amendment CMC
16-Nov-04	Submission to FDA	200	New Protocol/Study CDAR328A2305
22-Dec-04			NDA 21. 513 APPROVAL
07-Jan-05	Submission to FDA	201	Protocol Amendment/Study CDAR328A2403
10-Jan-05	Submission to FDA	202	Protocol Amendment/Study CDAR328A2409

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant During the Applicable Regulatory Review Period**

<b>Date</b>	<b>Activity</b>	<b>NDA 21, 513</b>	<b>Comments</b>
2-Dec-2002	Submission to FDA	X	NDA submission
10-Dec-2002	Submission to FDA	X	Proposal for 4-month safety update
30-Dec-2002	FDA fax	X	Notification that the Division has received the NDA for Enablex
3-Jan-2003	Submission to FDA	X	Provide 5 Desk copies of Module to DRUDP
13-Jan-2003	FDA fax	X	NDA CMC queries
20-Jan-2003	Submission to FDA	X	Response to CMC queries
24-Jan-2003	Submission to FDA	X	Information amendment clinical safety
30-Jan-2003	FDA log	X	NDA CMC queries
5-Feb-2003	FDA log	X	DSI Inspector called to request information
6-Feb-2003	Submission to FDA	X	Proposal for 4-month safety update
18-Feb-2003	Submission to FDA	X	Response to FDA request for information
18-Mar-2003	Submission to FDA	X	Response to FDA request for information
14-Mar-2003	FDA log	X	Filing issues identified - 74 day letter
20-Mar-2003	Submission to FDA	X	Response to FDA request for information - clinical sites
28-Mar-2003	Submission to FDA	X	Response to FDA request for information -financial disclosure
11-Jul-2003	FDA log	X	Questions from FDA
14-Apr-2003	Submission to FDA	X	General Correspondence - Manufacturing facility withdrawal
16-Apr-2003	Submission to FDA	X	Response to FDA request for information - 74 day letter
16-Apr-2003	Submission to FDA	X	Four-Month Safety update
23-Apr-2003	Submission to FDA	X	Pfizer Notification of NDA transfer
23-Apr-2003	Submission to FDA	X	Novartis Notification of Change of Ownership
21-Jul-2003	Submission to FDA	X	Response to FDA request for information - CMC
5-Aug-2003	Submission to FDA	X	Response to FDA request for information - statistical information
11-Aug-2003	Submission to FDA	X	Revised package insert
11-Aug-2003	Submission to FDA	X	Response to FDA request for information -statistics
12-Aug-2003	FDA log	X	Request for information
19-Aug-2003	Submission to FDA	X	Response to FDA request for information - Statistical
20-Aug-2003	Submission to FDA	X	Response to FDA request for information - clinical
21-Aug-2003	Submission to FDA	X	Response to FDA request for information - clinical
29-Aug-2003	Submission to FDA	X	Revised carton and container labels
5-Sep-2003	Submission to FDA	X	Response to FDA request for information - clinical
10-Sep-2003	Submission to FDA	X	Response to request for Information - CMC
11-Sep-2003	Submission to FDA	X	Response to FDA request for information - clinical
16-Sep-2003	FDA log	X	Request for information
18-Sep-2003	Submission to FDA	X	Response to FDA request for information - clinical (Study 1035)
19-Sep-2003	Submission to FDA	X	Response to FDA request for information - clinical Study (1007)

**APPENDIX F**

**Significant Activities Undertaken by the Marketing Applicant During the Applicable Regulatory Review Period**

19-Sep-2003	Submission to FDA	X	Response to FDA request for information - clinical
23-Sep-2003	Submission to FDA	X	Response to FDA request for information - CMC
2-Oct-2003	FDA log	X	Approvable letter
10-Oct-2003	Submission to FDA	X	Notification of intent to amend the NDA
4-Feb-2004	Submission to FDA	X	Analysis plan for update of Safety Data
20-Apr-2004	Submission to FDA	X	Meeting Request
23-Apr-2004	FDA log	X	Comments on safety update proposal
19-May-2004	Submission to FDA	X	Pre-submission briefing document
28-May-2004	Submission to FDA	X	Follow-up to e-mail requesting clarification of safety update
28-May-2004	Submission to FDA	X	Pre-submission briefing document - revised version
16-Jun-2004	Submission to FDA	X	Submission of Complete Response
21-Jun-2004	Submission to FDA	X	Resubmission of Complete Response - Electronic files
12-Jul-2004	FDA log	X	Comments on labeling
23-Jul-2004	FDA log	X	Response to request for meeting
27-Aug-2004	Submission to FDA	X	Submission of carton and container labels and response to comments
9-Sep-2004	FDA log	X	45-day Information
15-Sep-2004	Submission to FDA	X	Submission of draft risk management plan
17-Sep-2004	Submission to FDA	X	Response to information request
28-Sep-2004	Submission to FDA	X	Response to request for Information - clinical
30-Sep-2004	Submission to FDA	X	Proposed pediatric development plan
1-Oct-2004	Submission to FDA	X	Update of XML files
11-Oct-2004	Submission to FDA	X	Response to request for information
13-Oct-2004	FDA log	X	Meeting minutes Sept. 17, 2004
22-Oct-2004	Submission to FDA	X	Response to request for information
29-Oct-2004	FDA log	X	Meeting minutes Oct 14, 2004
24-Nov-2004	Submission to FDA	X	Response to request for revised carton and container labels
30-Nov-2004	FDA log	X	Revised package insert
1-Dec-2004	Submission to FDA	X	Request for information
6-Dec-2004	FDA log	X	CMC comments carton and container label
8-Dec-2004	Submission to FDA	X	Revised draft labeling
10-Dec-2004	Submission to FDA	X	Revised PPI and PI
14-Dec-2004	FDA log	X	Further comments on Package insert
16-Dec-2004	Submission to FDA	X	Revised PPI and PI
17-Dec-2004	Submission to FDA	X	Response to FDA
22-Dec-2004	FDA log	X	Approval Letter